Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and is expanding its incretin franchise with promising new drugs like retatrutide and Foundeo. In contrast, Merck's Q2 revenue grew only 5%, with KEYTRUDA's growth plateauing and the company facing a significant patent cliff. Merck is focusing on diversifying its portfolio with new launches like Lipvendra but faces uncertainty in timing and growth durability. Lilly's robust pipeline and raised guidance position it as a more durable growth story through 2030, while Merck may appeal more to value investors due to its lower valuation and dividend yield.
Following the contrasting growth stories of Eli Lilly and Merck, Eli Lilly's stock on Pluang is trading at USD 1,155.65 with a 1.57% gain as of Sep 15, 2026 19:16 WIB, reflecting strong investor interest. Merck's shares are priced at USD 143.80, down slightly by 0.13% at the same time, highlighting a more cautious market stance. Eli Lilly's market cap stands at $1.01 trillion, significantly larger than Merck's $357.37 billion, underscoring its dominant position in the health sector.
AbbVie’s stock trades near $277, close to a $279 price target, driven by strong growth in drugs Skyrizi and Rinvoq, and recent FDA approvals including JUVMO for Parkinson’s. The company’s acquisition of Apogee Therapeutics and raised revenue guidance...
Eli Lilly's biggest shareholder, the Lilly Endowment, filed to sell 300,000 shares worth $347 million, driven by a legal payout requirement rather than company performance concerns. Despite the sale, analysts continue to raise price targets, with Mor...
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
Eli Lilly's Phase 3b TOGETHER-PsO trial revealed that combining Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader changes in psoriasis and metabolic biomarkers compared to Taltz alone as early as Week 12. This suggests a linked immune-meta...
At the Veeva R&D and Quality Summit in Boston, leading biopharma companies like Eli Lilly, Pfizer, and Sanofi shared innovations in AI, cloud platforms, and connected trials to accelerate drug development and improve quality. Highlights include Eli L...
